LeishaAnnEmensMDPhD

Professor of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center; Co-Leader, Hillman Cancer Immunology and Immunotherapy Program; Director, Translational Immunotherapy for the Women's Cancer Research Center, Magee Women's Hospital

Join to view full profile

Dr. Emens is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Emens' full profile

Already have an account?

Office
600 N Wolfe St
Suite 4628
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 412-623-1212

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2002
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1995 - 1998
Baylor College of MedicineClass of 1995

Certifications & Licensure

CA State Medical License 2024 - 2026
MD State Medical License 1998 - 2026
PA State Medical License 2018 - 2024
TX State Medical License 1997 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 1
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer Start of enrollment: 2006 Sep 01
Completed
Phase 2
Cytokine Expression During Radiation for Breast Cancer Start of enrollment: 2009 Nov 13
Completed
Not Applicable
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 2
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Start of enrollment: 2019 Mar 08
Active, not recruiting
Phase 2
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Start of enrollment: 2020 Feb 24
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

704 citations
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficac...
Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H. Barrios
The Lancet. Oncology. 2020-01-01
247 citations
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Michaela J. Higgins, Danijela Jelovac, Evan Barnathan, Brian G. Blair, Shannon Slater
Clinical Cancer Research. 2012-06-15
547 citations
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios
The New England Journal of Medicine. 2018-11-29

Journal Articles

Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis
Sharon Solomon, Christopher H Lieu, Ashvini Reddy, Leisha A Emens, S Lindsey Davis, Lingmin He, JAMA

Lectures

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
Breast and Gynecologic Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

Ankyra Therapeutics Appoints Leisha a. Emens, M.D., Ph.D., as Senior Vice President, Translational ResearchDecember 7th, 2022
Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 4th, 2022
Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Breast CancerAugust 18th, 2021
Join now to see all